Citation:Qin HF,Shi FJ,Zhang CY,Luo DW,Qin SY,Wu J,Xie H,Zhang JT,Qiu QH,Liu K,Xu GT,Xu GX,Zhang JF.Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion.Int J Ophthalmol 2022;15(8):1296-1304,doi:10.18240/ijo.2022.08.11
Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion
Received:October 31, 2021  Revised:January 25, 2022
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2022.08.11
Key Words:macular edema  retinal vein occlusion  anti-VEGF  hyperreflective foci  non-perfusion area
Fund Project:Supported by the National Natural Science Foundation of China (No.81970811; No.81970810; No.82171062); Domestic Science and Technology Cooperation Project of Shanghai Municipal Science and Technology Commission (No.21015800700).
                                      
AuthorInstitution
Hai-Feng Qin Department of Ophthalmology, Changhai Hospital, Shanghai , China; Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou , Jiangsu Province, China
Fan-Jun Shi Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou , Jiangsu Province, China
Chao-Yang Zhang Department of Ophthalmology, Shanghai General Hospital Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai , China; National Clinical Research Center for Eye Diseases
Da-Wei Luo Department of Ophthalmology, Shanghai General Hospital Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai , China; National Clinical Research Center for Eye Diseases
Shi-Yue Qin Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou , Jiangsu Province, China
Jing Wu Shanghai Key Laboratory of Ocular Fundus Diseases
Hai Xie Shanghai Key Laboratory of Ocular Fundus Diseases
Jing-Ting Zhang Department of Ophthalmology, Shanghai General Hospital Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai , China; National Clinical Research Center for Eye Diseases
Qing-Hua Qiu Department of Ophthalmology, Shanghai General Hospital Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai , China; National Clinical Research Center for Eye Diseases; Shanghai Engineering Center for Visual Science and Photomedicine
Kun Liu Department of Ophthalmology, Shanghai General Hospital Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai , China; National Clinical Research Center for Eye Diseases
Guo-Tong Xu Shanghai Key Laboratory of Ocular Fundus Diseases
Guo-Xu Xu Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, Suzhou , Jiangsu Province, China
Jing-Fa Zhang Department of Ophthalmology, Shanghai General Hospital Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai , China; National Clinical Research Center for Eye Diseases
Hits: 176
Download times: 35
Abstract:
      AIM: To investigate the anti-inflammatory effect of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with macular edema secondary to retinal vein occlusion (RVO-ME).

    METHODS: Twenty-eight eyes from twenty-eight treatment-na?ve patients (14 males and 14 females) with RVO-ME were included in this retrospective study. The retinal vein occlusion (RVO) was comprised of both central retinal vein occlusion (CRVO, n=14) and branch retinal vein occlusion (BRVO, n=14). Intravitreal injection of anti-VEGF reagents were administered monthly for three consecutive months, in which 18 patients were injected with ranibizumab and 10 patients were injected with conbercept. All eyes were imaged with optical coherence tomography angiography (OCTA) at baseline and 1wk after monthly intravitreal anti-VEGF injection. The visual acuity (VA), central macular thickness (CMT), the number of hyperreflective foci (HRF) recognized as an inflammatory sign in OCT images, and non-perfusion area (NPA), were compared before and after anti-VEGF treatments.

    RESULTS: The mean interval between baseline and follow-up was 29.4±0.79 (range, 27-48)d. Compared with the baseline, the VA improved (logMAR 1.5±0.1 vs 0.8±0.1, P<0.05) and CMT decreased (460±34.0 μm vs 268.8±12.0 μm, P<0.05), significantly, after anti-VEGF treatment. The number of HRF was decreased significantly (76.5±4.8 vs 47.8±4.3, P<0.05) after anti-VEGF treatment.

    CONCLUSION: Anti-VEGF therapy is effective in treating RVO-ME. The mechanisms for the decreased HRF and the reduction of NPA by anti-VEGF therapy merits further exploration.

Supplementary Material
PDF Fulltext  Download reader  View/Add Comment